Hafezi and colleagues developed a GMP-compatible protocol for efficient adenine base editing of TIM3 and TIGIT in tumor-infiltrating lymphocytes, resulting in enhanced expansion, cytokine production, and serial cytolytic capacity. The gene discussed is HAVCR2; the disease is neoplasm.